Cautious Optimism As Genentech/AC Immune’s Anti-Tau Antibody Slows Cognitive Decline
Next Steps May Depend On Longer-Term Open-Label Data
AC Immune's CEO said semorinemab efficacy in mild-to-moderate Alzheimer's disease may relate to the tau species the antibody targets • Source: Alamy 
